Therapeutic anti-VEGF strategies have been implemented, e.g., bevacizumab, which is a VEGF-blocking antibody, was shown to be safe for glioblastoma patients’ treatment, also in combination with other therapeutics (for a review, see [139]). The gene discussed is VEGFA; the disease is glioblastoma.